名稱 | CCDC6-RET WT/BaF3 |
型號 | CBP73214 |
報價 | ![]() |
特點(diǎn) | CCDC6-RET WT/BaF3,母細(xì)胞:BaF3 |
產(chǎn)品搜索
相關(guān)文章
- NCRI:新型檢測技術(shù)或能提前8年診斷出食管癌
- 新型冠狀病毒:用于診斷的假病毒標(biāo)準(zhǔn)品和用于藥物研發(fā)的假病毒模型
- 血液系統(tǒng)惡性腫瘤治療研究熱點(diǎn)
- NIPT標(biāo)準(zhǔn)品-助力無創(chuàng)產(chǎn)前檢測
- *針對肝癌的PD-1抗體獲FDA批準(zhǔn),國產(chǎn)PD-1抗體進(jìn)入三期
- CSF3R細(xì)胞篩選模型
- 細(xì)胞株的一些篩選事項(xiàng)為您解讀
- 真實(shí)的“藍(lán)瘦香菇”長這樣
- HPV分子診斷標(biāo)準(zhǔn)品擴(kuò)容:精準(zhǔn)檢測,實(shí)力升級
- IL10及其受體細(xì)胞篩選模型
聯(lián)系我們
電話:4008750250
號碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73214CCDC6-RET WT/BaF3

- 詳細(xì)內(nèi)容
CBP73214 | |
I. Introduction | |
Cell Line Name: | CCDC6-RET WT/BaF3 |
Host Cell: | BA/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin |
Mycoplasma Status: | Negative |
II.Background | |
CCDC6, coiled-coil domain containing 6, has been shown to play a role in the DNA damaging signaling pathway acting as a substrate of ATM (PMID: 17420723). CCDC6 fusions with RET (PMID: 23154560, PMID: 26078337) and BRAF (PMID: 26314551) have been observed in multiple cancer types. | |
III. Representative Data | |
1. WB of CCDC6-RET WT/BaF3WT | |
2. Sanger of CCDC6-RET WT/BaF3 Figure 2. Breakpoint of CCDC6-RET WT/BaF3 | |
2. Anti-proliferation assay | |
Figure 3. CTG assay of for CCDC6-RET WT/BaF3 Stable Cell Line,the Gi50 was 137.3nM. |